Twenty‐five years of <i>Respirology</i>: Advances in COPD

Ko, Fanny W.S.; Sin, Don D.

doi:10.1111/resp.13734

Cited by 6 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, COPD patients do not bene t from inhaled corticosteroids (ICS) alone. ICS treatment neither delays the long-term decline of forced expiratory volume in one second nor reduces the mortality of COPD patients [4,5] . Although a number of studies have shown that COPD patients with blood eosinophil counts of ≥ 300/μL or ≥ 100/μL and with more than two moderate acute exacerbations or one hospitalization per year can bene t from ICS combined with one or two long-acting bronchodilators, other COPD patients do not receive such bene t [6] .…”

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Network Pharmacology and Molecular Docking Study of Jinwei Decoction for Enhancement of Glucocorticoid Anti-Inflammatory Effect in COPD through miR-21

Zhang

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposeJinwei decoction can enhance the anti-inflammatory effect of glucocorticoid (GC) on chronic obstructive pulmonary disease (COPD) by restoring the activity of HDAC2. But the upstream mechanism of Jinwei decoction on HDAC2 expression is not clear. ObjectiveTo explore whether Jinwei decoction can enhance the anti-inflammatory effect of GC on COPD through microRNA21 (miR-21) by network pharmacology. MethodsThe TCMSP database was used to screen active ingredients and target genes of Jinwei decoction, and miRWalk2.0 was used to predict downstream target genes of miR-21. COPD-related genes were identified by searching GeneCards and OMIM databases; Venny 2.1 was used to screen intersection genes; Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of intersection genes were analyzed by R software. Protein-protein interactions (PPIs) were analyzed by Cytoscape 3.7.2 software to identify core genes. Finally, interactions between main compounds and potential targets were verified by molecular docking. ResultsTwo hundred ninety-two active ingredients, 316 Jinwei drug targets, 10170 miR-21 target genes, 6617 COPD target genes, and 184 intersection gene were identified. Eleven core proteins of PPI networks may be involved. GO enrichment analysis showed that oxidative stress, regulation of inflammatory response, hormone transport, and histone modification were involved; KEGG pathway enrichment analysis concentrated in the PI3K-Akt, mitogen-activated protein kinase (MAPK), HIF-1, neutrophil extracellular bactericidal network, and other signaling pathways. ConclusionJinwei decoction can regulate histone deacetylase-2 activity and enhance the anti-inflammatory effect of GC on COPD by modulating miR-21. Its mechanism of action may be related to its effect on the PI3K Akt, MAPK, and TNF signaling pathways and neutrophil extracellular trap formation through miR-21.

show abstract

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Network Pharmacology and Molecular Docking Study of Jinwei Decoction for Enhancement of Glucocorticoid Anti-Inflammatory Effect in COPD through miR-21

Zhang

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Chronic obstructive pulmonary disease (COPD) is a kind of chronic bronchitis and / or emphysema with the characteristics of airflow obstruction, which can be further developed into a common chronic disease of pulmonary heart disease and respiratory failure (Hogea et al, 2020). It is related to the abnormal inflammatory reaction of harmful gases and particles (Ko & Sin, 2020). In recent years, with the aggravation of environmental pollution, COPD is threatening people's health more and more seriously, which has become a frequent and common disease.…”

Section: Introductionmentioning

confidence: 99%

Effect of Jianpibufei plaster on chronic obstructive pulmonary disease in mice

et al. 2021

View full text Add to dashboard Cite

“…The diversity of aetiologies of COPD, complex presentations, gaps in available management and different healthcare systems provide barriers to implementation of best practice care for patients with COPD, both globally and in regions such as the Asia‐Pacific. For clinicians providing day‐to‐day management, and for health policy makers shaping the system, keeping up‐to‐date with the ever‐expanding evidence in COPD epidemiology, diagnosis and management 2,3 is a rewarding but never‐ending challenge.…”

Section: Figurementioning

confidence: 99%